Bristol-Myers Squibb partners with Infinity Pharmaceuticals to evaluate Opdivo in combination with IPI-549 in advanced solid tumors.
M2 PHARMA-November 10, 2016-Bristol-Myers Squibb partners with Infinity Pharmaceuticals to evaluate Opdivo in combination with IPI-549 in advanced solid tumors
(C)2016 M2 COMMUNICATIONS
Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) reported on Wednesday the launch of a clinical trial to evaluate Opdivo and IPI-549 combination for treating advanced solid tumors in collaboration with Infinity Pharmaceuticals (NasdaqGS:INFI).
The clinical trial collaboration will evaluate Bristol-Myers' Opdivo in combination with Infinity Pharmaceuticals' IPI-549 in patients with advanced solid tumors with Infinity Pharmaceuticals (INFI).
IPI-549 is an oral immuno-oncology development candidate that is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma and is the only investigational PI3K-gamma inhibitor in clinical development; while Opdivo is a PD-1 immune checkpoint inhibitor, according to the companies.
This ongoing Phase 1 dose-escalation clinical study is designed to explore the activity, safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy and in combination with Opdivo in approximately 175 patients with advanced solid tumors.
Upon completion of the the dose-escalation phase evaluating Opdivo plus IPI-549, an expansion phase is planned to evaluate the combination in patients with selected solid tumors, including non-small cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of the head and neck (SCCHN), said the companies.
Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world in July 2014 and currently has regulatory approval in 54 countries including the United States, Japan, and in the EU, concluded the companies.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 10, 2016|
|Previous Article:||MEI Pharma's net loss reduces to USD4.3m for Q1 fiscal 2017.|
|Next Article:||Assembly Biosciences begins Phase 1 clinical trial of ABI-H0731 for treating chronic hepatitis B virus infection.|